Posted inDermatology Diabetes & Endocrinology news
SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study
A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.